Carlumab

Source: Wikipedia, the free encyclopedia.
Carlumab
MCP-1
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6442H9966N1706O2018S40
Molar mass144884.91 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Carlumab (alternate identifier CNTO 888

liver fibrosis and type 2 diabetes.[2]

The inhibitory binding of Carlumab to CCL2 was hypothesized to inhibit angiogenesis and consequently modulate tumor cell proliferation.[3][2] Studies focusing on the effects of Carlumab have been performed in vitro on cell lines and in vivo on mice and in humans including phase 1 and phase 2 clinical trials evaluating the efficacy, safety and dose requirements of the drug. Clinical trials for Carlumab include studies of idiopathic pulmonary fibrosis,[8][9] castration-resistant metastatic prostate cancer[1][10] and solid tumors.[11][12]

Carlumab was being developed by Janssen Biotech prior to discontinuation in 2012[13] due to limited success in clinical trials.

References

  1. ^
    S2CID 29365102
    .
  2. ^ a b c "CNTO-888/Carlumab" (PDF). Janssen (J&J). Archived from the original (PDF) on 2017-01-31. Retrieved 2017-03-24.
  3. ^ a b "Carlumab". NCI Drug Dictionary. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute (NCI). 2011-02-02. Retrieved 2017-03-24.
  4. S2CID 10638060
    .
  5. PMID 22487721
    .
  6. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Carlumab" (PDF). American Medical Association.
  7. ISSN 1010-9609
    . Retrieved 17 August 2015.
  8. PMID 26493793
    .
  9. ^ Clinical trial number NCT00786201 for "A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)" at ClinicalTrials.gov
  10. ^ Clinical trial number NCT00992186 for "A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer" at ClinicalTrials.gov
  11. S2CID 23586468
    .
  12. ^ Clinical trial number NCT00537368 for "First Study of the Safety of CNTO 888 in Patients With Solid Tumors" at ClinicalTrials.gov
  13. ^ "Annual Report 2012: Research and Development". MorphoSys. 2012. Retrieved 2017-03-24.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Carlumab&oldid=1161944825"